{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:11:18Z","timestamp":1769825478995,"version":"3.49.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cld.2022.06.004","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T20:49:54Z","timestamp":1666126194000},"page":"613-627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Autoantibodies in Primary Biliary Cholangitis"],"prefix":"10.1016","volume":"26","author":[{"given":"Kristel K.","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon M.","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10266","key":"10.1016\/j.cld.2022.06.004_bib1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cld.2022.06.004_bib2","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","article-title":"Recent advances in clinical practice: epidemiology of autoimmune liver diseases","volume":"70","author":"Trivedi","year":"2021","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.cld.2022.06.004_bib3","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jgh.15329","article-title":"Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis","volume":"36","author":"Lv","year":"2021","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.004_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2022.06.004_bib5","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2022.06.004_bib6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.004_bib8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.immuni.2015.02.002","article-title":"Mitochondria in the regulation of innate and adaptive immunity","volume":"42","author":"Weinberg","year":"2015","journal-title":"Immunity"},{"issue":"7285","key":"10.1016\/j.cld.2022.06.004_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature08780","article-title":"Circulating mitochondrial DAMPs cause inflammatory responses to injury","volume":"464","author":"Zhang","year":"2010","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.cld.2022.06.004_bib10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1515\/cclm-2013-0926","article-title":"The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis","volume":"52","author":"Hu","year":"2014","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0168-8278(99)80302-X","article-title":"Anti-pyruvate dehydrogenase autoantibodies in extrahepatic disorders","volume":"31","author":"Zamfir","year":"1999","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.004_bib12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/hep.510270303","article-title":"Characterization of antimitochondrial antibodies in health adults","volume":"27","author":"Mattalia","year":"1998","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib13","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/hep.21828","article-title":"Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis","volume":"46","author":"Leung","year":"2007","journal-title":"Hepatology"},{"issue":"7390","key":"10.1016\/j.cld.2022.06.004_bib14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(65)91372-3","article-title":"Serological tests in diagnosis of primary biliary cirrhosis","volume":"1","author":"Walker","year":"1965","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1034\/j.1600-0528.2002.017402.x","article-title":"Primary biliary cirrhosis: an orchestrated immune response against epithelial cells","volume":"174","author":"Gershwin","year":"2000","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.cld.2022.06.004_bib16","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/hep.1840110611","article-title":"Inhibition of alpha-ketoglutarate dehydrogenase activity by a distinct population of autoantibodies recognizing dihydrolipoamide succinyltransferase in primary biliary cirrhosis","volume":"11","author":"Fregeau","year":"1990","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2022.06.004_bib17","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1073\/pnas.87.10.3987","article-title":"Reactivity of primary biliary cirrhosis sera with Escherichia coli dihydrolipoamide acetyltransferase (E2p): characterization of the main immunogenic region","volume":"87","author":"Fussey","year":"1990","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib18","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.20907","article-title":"Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients","volume":"42","author":"Gershwin","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/cei.13198","article-title":"Pathogen infections and primary biliary cholangitis","volume":"195","author":"Tanaka","year":"2019","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.004_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/hep.32172","article-title":"E.\u00a0coli and the etiology of human PBC: antimitochondrial antibodies and spreading determinants","volume":"75","author":"Yang","year":"2022","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2022.06.004_bib21","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI0214698","article-title":"Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis","volume":"109","author":"Kita","year":"2002","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.cld.2022.06.004_bib22","first-page":"1031","article-title":"Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1\/B7 expression","volume":"21","author":"Tsuneyama","year":"1995","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2022.06.004_bib23","first-page":"237","article-title":"Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications","volume":"1","author":"Doniach","year":"1966","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hep.510250103","article-title":"Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression","volume":"25","author":"Van Norstrand","year":"1997","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.06.004_bib25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1309\/AJCPQV4A7QAEEFEV","article-title":"The significance of autoantibody changes over time in primary biliary cirrhosis","volume":"144","author":"Tana","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.cld.2022.06.004_bib26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s10875-007-9092-0","article-title":"Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis","volume":"27","author":"Gabeta","year":"2007","journal-title":"J\u00a0Clin Immunol"},{"issue":"609","key":"10.1016\/j.cld.2022.06.004_bib27","article-title":"Autoantibodies in autoimmune liver disease\u2014clinical and diagnostic relevance. Review","volume":"9","author":"Sebode","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hep.28859","article-title":"Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis","volume":"65","author":"Dahlqvist","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2022.06.004_bib29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gut.2003.023937","article-title":"Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort","volume":"53","author":"Prince","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.cld.2022.06.004_bib30","doi-asserted-by":"crossref","first-page":"102578","DOI":"10.1016\/j.jaut.2020.102578","article-title":"Primary biliary cholangitis with normal alkaline phosphatase: a neglected clinical entity challenging current guidelines","volume":"116","author":"Terziroli Beretta-Piccoli","year":"2021","journal-title":"J\u00a0Autoimmun"},{"issue":"2","key":"10.1016\/j.cld.2022.06.004_bib31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cld.2022.06.004_bib32","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.004_bib33","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/hep.1840060609","article-title":"Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?","volume":"6","author":"Mitchison","year":"1986","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.06.004_bib34","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3892\/etm.2015.2694","article-title":"Anti-mitochondrial M2 antibody-positive autoimmune hepatitis","volume":"10","author":"Tomizawa","year":"2015","journal-title":"Exp Ther Med"},{"issue":"3","key":"10.1016\/j.cld.2022.06.004_bib35","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.exphem.2005.12.011","article-title":"The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery","volume":"34","author":"Patriarca","year":"2006","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.004_bib36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/jhep.2001.26514","article-title":"Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens","volume":"34","author":"Miyakawa","year":"2001","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2022.06.004_bib37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0676.1997.tb01033.x","article-title":"Clinicopathological study of primary biliary cirrhosis negative for antimitochondrial antibodies","volume":"17","author":"Nakanuma","year":"1997","journal-title":"Liver"},{"issue":"3","key":"10.1016\/j.cld.2022.06.004_bib38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12016-010-8234-y","article-title":"Overcoming a \"probable\" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature","volume":"42","author":"Bizzaro","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib39","first-page":"1440","article-title":"Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody\u2014negative primary biliary cirrhosis","volume":"22","author":"Tsuneyama","year":"1995","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2022.06.004_bib40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3109\/00365521.2015.1132337","article-title":"Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis","volume":"51","author":"Juliusson","year":"2016","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib41","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.25511","article-title":"Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis","volume":"55","author":"Jin","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2022.06.004_bib42","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/liv.14688","article-title":"Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis","volume":"41","author":"Haldar","year":"2021","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.cld.2022.06.004_bib43","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gut.46.4.553","article-title":"Liver\/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane","volume":"46","author":"Muratori","year":"2000","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2022.06.004_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5387\/fms.58.107","article-title":"Autoantibodies by line immunoassay in patients with primary biliary cirrhosis","volume":"58","author":"Saito","year":"2012","journal-title":"Fukushima J Med Sci"},{"issue":"4","key":"10.1016\/j.cld.2022.06.004_bib45","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jaut.2010.09.005","article-title":"PBC screen: an IgG\/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis","volume":"35","author":"Liu","year":"2010","journal-title":"J\u00a0Autoimmun"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib46","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.510230512","article-title":"Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis","volume":"23","author":"Bandin","year":"1996","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1586\/erm.11.82","article-title":"Antinuclear antibodies as ancillary markers in primary biliary cirrhosis","volume":"12","author":"Granito","year":"2012","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13223-021-00539-0","article-title":"Autoantibodies to speckled protein family in primary biliary cholangitis","volume":"17","author":"Granito","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.004_bib49","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s12026-021-09233-0","article-title":"How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative","volume":"69","author":"von M\u00fchlen","year":"2021","journal-title":"Immunol Res"},{"issue":"11\u201312","key":"10.1016\/j.cld.2022.06.004_bib50","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/j.1365-2036.2006.03172.x","article-title":"Antinuclear antibodies giving the 'multiple nuclear dots' or the 'rim-like\/membranous' patterns: diagnostic accuracy for primary biliary cirrhosis","volume":"24","author":"Granito","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.cld.2022.06.004_bib51","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1590-8658(03)00466-3","article-title":"Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection","volume":"35","author":"Bogdanos","year":"2003","journal-title":"Dig Liver Dis"},{"issue":"7","key":"10.1016\/j.cld.2022.06.004_bib52","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0016-5085(03)00387-1","article-title":"Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis","volume":"124","author":"Shimoda","year":"2003","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib53","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/hep.30604","article-title":"Genome-wide association studies of specific antinuclear autoantibody subphenotypes in primary biliary cholangitis","volume":"70","author":"Wang","year":"2019","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"10.1016\/j.cld.2022.06.004_bib54","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.24705","article-title":"Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis","volume":"55","author":"Umemura","year":"2012","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.06.004_bib55","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/gut.2003.036558","article-title":"Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis","volume":"54","author":"Rigopoulou","year":"2005","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.cld.2022.06.004_bib56","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.14309\/ajg.0000000000000690","article-title":"Novel anti-hexokinase 1 antibodies are associated with poor prognosis in patients with primary biliary cholangitis","volume":"115","author":"Reig","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib57","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib58","first-page":"1123","article-title":"Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis","volume":"26","author":"Z\u00fcchner","year":"1997","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.004_bib59","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","article-title":"Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis","volume":"98","author":"Muratori","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2022.06.004_bib60","doi-asserted-by":"crossref","first-page":"9121207","DOI":"10.1155\/2019\/9121207","article-title":"Early prognostic utility of gp210 antibody-positive rate in primary biliary cholangitis: a meta-analysis","volume":"2019","author":"Huang","year":"2019","journal-title":"Dis Markers"},{"issue":"3","key":"10.1016\/j.cld.2022.06.004_bib61","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jhep.2004.11.016","article-title":"Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis","volume":"42","author":"Nakamura","year":"2005","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib62","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/hep.21172","article-title":"Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis","volume":"43","author":"Wesierska-Gadek","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib63","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1055\/s-2007-1007184","article-title":"Autoantibodies against \"nuclear dots\" in primary biliary cirrhosis","volume":"17","author":"Szostecki","year":"1997","journal-title":"Semin Liver Dis"},{"issue":"3","key":"10.1016\/j.cld.2022.06.004_bib64","first-page":"609","article-title":"Small ubiquitin-related modifiers: a novel and independent class of autoantigens in primary biliary cirrhosis. Hepatology","volume":"41","author":"Janka","year":"2005","journal-title":"Mar"},{"issue":"4","key":"10.1016\/j.cld.2022.06.004_bib65","article-title":"Analysis of Autoantibodies against promyelocytic leukemia nuclear body components and biochemical parameters in sera of patients with primary biliary cholangitis","volume":"11","author":"Bauer","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"10.1016\/j.cld.2022.06.004_bib66","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/liv.12690","article-title":"Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis","volume":"35","author":"Norman","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2022.06.004_bib67","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3389\/fimmu.2019.00662","article-title":"The prevalence of anti-hexokinase-1 and anti-kelch-like 12 peptide antibodies in patients with primary biliary cholangitis is similar in Europe and North America: a large international, multi-center study","volume":"10","author":"Norman","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1479-7364-7-13","article-title":"Update on the Kelch-like (KLHL) gene family","volume":"7","author":"Dhanoa","year":"2013","journal-title":"Hum Genomics"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib69","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4161\/cc.4.5.1678","article-title":"Mitochondrial hexokinases: guardians of the mitochondria","volume":"4","author":"Robey","year":"2005","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib70","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-3083.2006.01747.x","article-title":"Anti-p97\/VCP antibodies: an autoantibody marker for a subset of primary biliary cirrhosis patients with milder disease?","volume":"63","author":"Miyachi","year":"2006","journal-title":"Scand J Immunol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.004_bib71","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1572-0241.2007.01136.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes","volume":"102","author":"Silveira","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib72","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12016-015-8516-5","article-title":"The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis","volume":"50","author":"Yang","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.004_bib73","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome","volume":"44","author":"Chazouill\u00e8res","year":"2006","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib74","first-page":"1449","article-title":"Treatment of overlap syndromes in autoimmune liver disease: a systematic review and meta-analysis","volume":"9","author":"Freedman","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"7785","key":"10.1016\/j.cld.2022.06.004_bib75","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile acid metabolites control TH17 and Treg cell differentiation","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"issue":"7903","key":"10.1016\/j.cld.2022.06.004_bib76","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41586-022-04480-z","article-title":"Human gut bacteria produce TH17-modulating bile acid metabolites","volume":"603","author":"Paik","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cld.2022.06.004_bib77","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis\u2013autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouill\u00e8res","year":"1998","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2022.06.004_bib78","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/ajg.2009.126","article-title":"The serological profile of the autoimmune hepatitis\/primary biliary cirrhosis overlap syndrome","volume":"104","author":"Muratori","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.004_bib79","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1155\/2012\/890698","article-title":"Clinical significance of autoantibodies to p53 protein in patients with autoimmune liver diseases","volume":"26","author":"Himoto","year":"2012","journal-title":"Can J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.004_bib80","doi-asserted-by":"crossref","first-page":"e0193960","DOI":"10.1371\/journal.pone.0193960","article-title":"Evaluation of classical and novel autoantibodies for the diagnosis of primary biliary cholangitis-autoimmune hepatitis overlap syndrome (PBC-AIH OS)","volume":"13","author":"Nguyen","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2022.06.004_bib81","article-title":"Anti-double stranded DNA antibodies: origin, pathogenicity, and targeted therapies. Review","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.cld.2022.06.004_bib82","first-page":"1777","article-title":"p53 Antibodies in the sera of patients with various types of cancer: a review","volume":"60","author":"Soussi","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.cld.2022.06.004_bib83","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bpg.2018.05.013","article-title":"PBC and related extrahepatic diseases","volume":"34-35","author":"Floreani","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib84","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/ajg.2016.479","article-title":"Thyroid dysfunction in primary biliary cholangitis: a comparative study at two european centers","volume":"112","author":"Floreani","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.cld.2022.06.004_bib85","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/BF03346432","article-title":"Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders","volume":"31","author":"Nakamura","year":"2008","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib86","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/gut.42.1.120","article-title":"The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences","volume":"42","author":"Kingham","year":"1998","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2022.06.004_bib87","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2036.2005.02328.x","article-title":"Autoimmune cholestatic liver disease in people with coeliac disease: a population-based study of their association","volume":"21","author":"Lawson","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib88","first-page":"44","article-title":"Prevalence of celiac disease in patients with primary biliary cholangitis","volume":"4","author":"Callichurn","year":"2021","journal-title":"J\u00a0Can Assoc Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib89","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3748\/wjg.v23.i5.776","article-title":"To screen or not to screen? Celiac antibodies in liver diseases","volume":"23","author":"Narciso-Schiavon","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib90","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/jcla.20130","article-title":"Low specificity of anti-tissue transglutaminase antibodies in patients with primary biliary cirrhosis","volume":"20","author":"Bizzaro","year":"2006","journal-title":"J\u00a0Clin Lab Anal"},{"issue":"4","key":"10.1016\/j.cld.2022.06.004_bib91","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1590-8658(02)80145-1","article-title":"Prevalence of coeliac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult coeliac disease patients in Italy","volume":"34","author":"Floreani","year":"2002","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib92","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2009.08.009","article-title":"A\u00a0comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis","volume":"34","author":"Agmon-Levin","year":"2010","journal-title":"J\u00a0Autoimmun"},{"issue":"29","key":"10.1016\/j.cld.2022.06.004_bib93","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.3748\/wjg.v16.i29.3616","article-title":"Primary biliary cirrhosis: what do autoantibodies tell us?","volume":"16","author":"Hu","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.004_bib94","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0896-8411(03)00033-7","article-title":"Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study","volume":"20","author":"Miyachi","year":"2003","journal-title":"J\u00a0Autoimmun"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib95","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/sarh.2001.20266","article-title":"Anti-nuclear envelope antibodies: clinical associations","volume":"30","author":"Nesher","year":"2001","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib96","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/annrheumdis-2020-218881","article-title":"Anti-centromere antibodies target centromere\u2013kinetochore macrocomplex: a comprehensive autoantigen profiling","volume":"80","author":"Kajio","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.cld.2022.06.004_bib97","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/ard.41.6.612","article-title":"Anticentromere antibody in primary biliary cirrhosis","volume":"41","author":"Bernstein","year":"1982","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.cld.2022.06.004_bib98","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2230.1994.tb01199.x","article-title":"Anticentromere antibodies (ACA): clinical distribution and disease specificity","volume":"19","author":"Chan","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"10.1016\/j.cld.2022.06.004_bib99","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3109\/00365529108998588","article-title":"High prevalence of autoimmune liver disease in patients with multiple nuclear dot, anti-centromere, and mitotic spindle antibodies","volume":"26","author":"Hansen","year":"1991","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.004_bib100","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/gut.2005.075002","article-title":"Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis","volume":"55","author":"Rigamonti","year":"2006","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.cld.2022.06.004_bib101","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3748\/wjg.v19.i7.1111","article-title":"Risk factors for hepatic decompensation in patients with primary biliary cirrhosis","volume":"19","author":"Shi","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.004_bib102","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clim.2006.01.002","article-title":"Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases","volume":"119","author":"Zachou","year":"2006","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.004_bib103","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jcla.21723","article-title":"High frequency of antiphospholipid antibodies in primary biliary cirrhosis","volume":"29","author":"Manka\u00ef","year":"2015","journal-title":"J\u00a0Clin Lab Anal"},{"issue":"5","key":"10.1016\/j.cld.2022.06.004_bib104","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10875-008-9211-6","article-title":"IgA anti-b2GPI antibodies in patients with autoimmune liver diseases","volume":"28","author":"Gabeta","year":"2008","journal-title":"J\u00a0Clin Immunol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.004_bib105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cld.2008.02.009","article-title":"Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value","volume":"12","author":"Muratori","year":"2008","journal-title":"Clin Liver Dis"},{"issue":"7","key":"10.1016\/j.cld.2022.06.004_bib106","doi-asserted-by":"crossref","first-page":"e101916","DOI":"10.1371\/journal.pone.0101916","article-title":"Meta-analysis assessment of gp210 and sp100 for the diagnosis of primary biliary cirrhosis","volume":"9","author":"Hu","year":"2014","journal-title":"PLoS One"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:59:54Z","timestamp":1761069594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326122000423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":106,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1089326122000423"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2022.06.004","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoantibodies in Primary Biliary Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2022.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}